Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)

Not Applicable

Terminated

• Conditions: Heart Failure
• Interventions: Device: Neuromuscular electrical stimulation; Device: Transcutaneous electrical stimulation

• Registration Number: NCT03615469
• Lead Sponsor: Indiana University

Brief Summary

In the U.S., 5.7 million people have heart failure (HF), 915,000 new cases are diagnosed each year, and both incidence and prevalence are increasing due to the aging of the population and to better survival from ischemic heart disease. A hallmark of HF, is poor functional status that, characteristically, deteriorates as the condition progresses, negatively affecting patients' quality of life. Poor functional status is associated with increased risk of hospitalization for exacerbations of HF and with increased mortality. Optimization of drug therapy and appropriate use of resynchronization therapy can improve functional status, as can patient engagement in exercise. Although exercise is recommended as a component of HF management, adherence is consistently low. This is particularly troubling because exercise has great potential as a low-risk, low-cost intervention to improve functional status and quality of life while decreasing HF symptoms and hospitalizations in patients with HF. Low adherence is due in part to inadequate strength and inability to tolerate or sustain even low levels of activity. In this study, we propose to use neuromuscular electrical stimulation (NMES) to assist patient initiation of quadriceps strengthening in order to progressively increase low exercise tolerance. NMES has been shown to improve muscle strength, exercise capacity and quality of life, in samples less than 20 of male patients with HF. Larger sample studies are needed to demonstrate efficacy of this practice to jump start patients' abilities to benefit from formalized exercise program. The purpose of this double blinded, randomized, controlled, longitudinal study is to determine if NMES will increase muscle mass and strength, decrease sedentary time, and improve HF symptoms and exercise capacity, thus improving quality of life in patients with HF. It is hypothesized that with this increase in muscle mass, patients will improve overall exercise tolerance and capacity. In addition, after the intervention patients will be better able to tolerate an exercise program thus improving adherence to exercise recommendations. After 6 weeks of intervention, patients will be encouraged to participate in a formalized exercise program.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-07-20
• Study First Submitted QC: 2018-08-02
• Study First Posted: 2018-08-03
• Study Start: 2018-09-06
• Primary Completion: 2020-07-01
• Study Completion: 2020-12-01
• Results First Submitted: 2021-05-11
• Status Verified: 2023-05
• Results First Submitted QC: 2023-05-08
• Last Update Submitted: 2023-05-08
• Results First Posted: 2023-05-31
• Last Update Posted: 2023-05-31

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Adult patients who have recently been hospitalized for heart failure
• live at home
• are receiving guideline recommended pharmacologic therapy
• do not regularly exercise (10 minutes or more a day of exercise most days of the week for the past week).

Read More

Exclusion Criteria

• Patients, who have undertaken cardiac rehab within the 12 months prior to enrollment
• Cognitive or other impairment which prevents accurate application of intervention or inability to provide informed consent
• End Stage Renal Disease or receiving mechanical ventilation
• Receiving non-approved FDA-investigational agents or devices,
• Has received a heart transplant, a destination Ventricular Assist Device (LVAD), pacemaker, or implantable cardiac device
• previously used NMES (Neuromuscular electrical stimulation) or TENS (Transcutaneous electrical nerve stimulation)
• Uncontrolled arrhythmia's or 3 degree AV heart block
• are unable to correctly apply and operate the device even after instruction
• Those with wounds over area of proper placement of electrodes
• Those who are unable to speak and write English.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Neuromusclar electrical stimulation	Neuromuscular electrical stimulation	NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the "self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border" as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time.
Transcutaneous electrical stimulation	Transcutaneous electrical stimulation	For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation

Primary Outcome Measures

Name	Time	Method
Change in 6 Minute Walk Test	From Baseline to 5-6 months	The 6-min walk test (6MWT) estimates the person's ability to perform everyday activities by measuring the distance walked in a set time period. It will be used to measure exercise capacity, specific aim 2. Participants will be allowed use of an assistive device and will be instructed to move as quickly as they feel safe and comfortable over the 100-meter course for 6 minutes. As per the protocol, participants will be allowed to stop and rest if necessary. This test is recommended by the American Thoracic Society for patients with moderate to severe heart or lung disease.

Trial Locations

Locations (1)

Indiana University; 🇺🇸 Indianapolis, Indiana, United States